September 2022 Research Summary:
A propensity-matched analysis underscores the need for optimal management of patients undergoing PCI for a heart attack or acute myocardial infarction.
Alerting Clinicians to 1-Year Mortality Risk in Patients Hospitalized With Heart Failure
The REVeAL-HF (Risk Evaluation and its Impact on Clinical Decision Making and Outcomes in Heart Failure) trial assessed whether provision of mortality estimates impacted clinical decision-making and outcomes in hospitalized patients with heart failure. The results appear in JAMA Cardiology.
With the support of the American Physician Scientists Association (APSA), researchers conducted a national survey of more than 2,000 physician-scientist trainees and faculty.
In this systematic review and meta-analysis, researchers investigated the effects of using DAPT for 1 to 3 months compared with 6 to 12 months to prevent ischemia.